Introduction: Gleason Score (GS) upgrading rates in the literature are reported to be around 33-45%. The relationship between prostate volume and GS upgrading should be defined, aiming to reduce upgrading rates in patients with low risk groups who are eligible for active surveillance (AS) or minimally invasive treatment, by varying biopsy cores, or lengths of cores according to prostate volumes. In this regard, the aim of our study was to establish the relationship between prostate volume and GS upgrading. Materials and methods: We retrospectively analyzed the medical records of 78 patients, who were appropriate for AS between 2011-2016 at our hospital. Inclusion criteria were patient age under 65 years, PSA level under 10 ng/ml, GS (3 + 3) or (3 + 4), and 3 or less positive cores, clinical stages ≤ T2. GS increase in radical prostatectomy specimen was considered as 'upgrading' and in addition, score reported by biopsy as 3 + 4 but in surgical specimen as 4 + 3 were also considered as 'upgrading'. The effect of prostate volume on Gleason grade upgrading was examined by calculating upgrading rates separately for patients with prostate volume 30 ml or less, those with 30 to 60 ml, and those over 60 ml. Results: As a result of the analysis of the data, upgrading was seen in 35 (44.8%) of 78 patients included in the study. In the cohort mean prostate volume was 49.8 (± 26.3) ml. Twenty-two patients (28.2%) had prostate volume 30 ml or less, 34 (43.6%) 30 to 60 ml, and 22 (28.2%) 60 ml or more. The patients were divided into two groups as those with and without GS upgrading. Between the groups prostate volume and prostate volume range (0-30/31-60/> 60) were not significantly different (p value > 0.05). Conclusions: Gleason grade upgrading causes patients to be classified in a lower risk group than they actually are, and may lead to inappropriate treatment. This condition has a direct effect on the decision of active surveillance. Therefore, it is important to define the factors that can predict GS upgrading in active surveillance appropriate patients. In this study, we found that prostate volume has no significant effect on upgrading in active surveillance appropriate patients. 
INTRODUCTION
Prostate cancer is the second most common cancer worldwide and the fifth most common cause of cancerrelated deaths. Because of this reason, there are lots of studies on prostate cancer (1) (2) . Active surveillance (AS) has been defined in the appropriate group of patients for low-risk prostate cancer. Gleason Score (GS) is the most important criteria for patient selection for AS and used in the nomograms. In most studies and nomograms (3+3) GS in the biopsy is used as an inclusion criterium. Recently, researchers have included some eligible patients with a biopsy GS 3 + 4 to their studies (3) (4) (5) (6) . In patients, considered AS option, all pathological data, including GS are dependent on prostate needle biopsy. So that, the accuracy of the GS in needle biopsies is very important for this patient groups. However, there may be a significant difference between GSs in needle biopsies and radical prostatectomy specimens. If the score in prostatectomy specimen is higher than needle biopsy, that is defined as 'upgrading', if it is lower, 'downgrading' is mentioned. Upgrading rates in the literature are reported to be around 33-45% (7). Because of upgrading, patients who are not actually suitable for AS can be recommended with inappropriate treatment options. The reason for this high pathological disruption seems to be that less than 1% of the prostate tissue can be sampled with needle biopsy. Assessment in such a small tissue volume can cause tumor tissue to be undetectable or even missed (8) (9) . This is supported by studies showing that rates of upgrading in needle biopsies of enlarged prostate are lower (10) (11) (12) (13) (14) . In most of previous studies, an inverse correlation was found between prostate volume and upgrading rates (15) (16) (17) . Kulkarni et al. have not found significant relationship between prostate volume and upgrading rates, in a retrospective study published in 2006 in which they reviewed 369 patients (18) . If the relationship between prostate volume and GS upgrading can be assessed, it may be aimed to reduce upgrading rates in patients with low risk groups who are DOI: 10.4081/aiua.2019.2.93 eligible for active follow-up or minimally invasive treatment, by varying biopsy cores, or lengths of cores according to their prostate volumes. In this regard, the aim of our study is to establish the relationship between prostate volume and GS upgrading. Inclusion criteria were patient age under 65 years, PSA level under 10 ng/ml, GS (3+3) or (3+4), and 3 or less positive cores, clinical stages ≤ T2. Prostate volumes were measured transrectally during biopsy, all biopsies were 12 cores and pathologic examination was performed by two experienced uro-pathologists in our hospital. GS, total cores, and cancer positive core numbers were noted in the biopsy specimens that detected adenocarcinoma. The length or percentage of the cancer positive tissue couldn't found in most reports. GS, PIN, surgical marginal status, PNI, SVI, ECE, presence of vascular invasion were registered. Biopsy and prostatectomy specimens were evaluated according to 2005 International Society of Uro-pathologists (ISUP) modified Gleason system. GS increase in radical prostatectomy specimen was assessed as 'upgrading' and in addition also cases in which the score reported by biopsy was 3 + 4 and the score found in the specimen was 4 + 3 were evaluated as 'upgrading'. The effect of prostate volume on Gleason grade upgrading was examined. Patients initially were divided into GS upgrading or not. These groups were compared in terms of age, PSA value, prostate volume, number of total biopsy cores, number of positive cores, clinical stages, surgical margin status, and SVI, presence of ECE, PIN, PNI, and vascular invasion. Upgrading rates were calculated separately for patients with prostate volume 30 ml or less, those with 30 to 60 ml, and those over 60 ml. In the descriptive statistics of the data, mean, standard deviation, median lowest, highest, frequency and ratio values were used. The distribution of the variables was measured with the Kolmogorov Simirnov test. Mann-Whitney U test was used for quantitative independent data analysis. Chi-square test was used for the analysis of qualitative independent data and SPSS 22.0 (Statistical Package for the Social Sciences) program was used in the analysis. P value below 0.05 were considered statistically significant (p < 0.05).
MATERIALS AND METHODS

We
RESULTS
As a result of the analysis of the data, upgrading was seen in 35 (44.8%) of 78 patients included in the study. The mean age of patients included in the study was 60.6 (± 4.4) years, and the mean PSA was 6.0 (± 2.2) ng/ml. According to needle biopsy reports, 65 patients (83.3%) had a GS of (3 + 3) and 13 patients (16.7%) had (3 + 4). In cohort mean prostate volume was 49.8 (± 26.3) ml. Twenty-two patients (28.2%) have prostate volume 30 ml or less, 34 (43.6%) 30 to 60 ml, and 22 (28.2%) 60 ml or more. The demographic and clinico-pathological outcomes of the patients included in the study are summarized in the 
DISCUSSION
Treatment options in prostate cancer differ according to defined risk groups. Low risk patients have better prognosis than middle and high risk group and lower biochemical recurrence rates after radical prostatectomy. In these patients, active follow-up, brachytherapy and focal therapies are used in order to avoid the complications and side effects of radical prostatectomy or radiotherapy (17, (19) (20) . PSA level, clinical stage and GS are used to determine these risk classification (21) (22) . GS is the most important prognostic factor of prostate cancer risk for classification and choice of treatment options (16, (22) (23) . Accurate determination of patient's risk group and GS at the time of diagnosis is important in order to choose the appropriate treatment options. However, there are significant pathological differences between needle biopsies and radical prostatectomy specimens such as GS upgrading in 33-45%. This high rate led investigators to examine the factors that might be effective to predict upgrading. PSA level, number of cores taken, number of positive cores are some of these factors. Also there are several studies on the effect of prostate volume on GS upgrading. (10, 15, (24) (25) (26) (27) 
CONCLUSIONS
Treatment alternatives in prostate cancer may differ according to risk groups. So that it is important to classify patients in the correct risk group. Gleason grade upgrading causes patients to be classified in a lower risk group than they actually are, and may lead to inappropriate treatment. This situation has a direct effect on the decision of active surveillance. Therefore, it is important to define the factors that can predict GS upgrading in active surveillance appropriate patients. In this study, we found that prostate volume has no significant effect on upgrading in active surveillance appropriate patients.
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